Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Top Page
Vivos Therapeutics
(NASDAQ:VVOS)
Rating:47Neutral
Price Target:
$2.50
▲( 19.62% Upside)
Positive Factors
Cost Control
Operating expenses in Q4 FY24 were down 21% yoy to $4.9 million, reflecting the company’s ongoing focus on cost control.
Regulatory Approvals
FDA approves use of Vivos CARE appliances to treat moderate to severe OSA in children, a first in the industry.
Revenue Growth
Vivos's new selling model can result in 4-6 times as much revenue per case while accessing many more patients with healthy margins.
Negative Factors
Financing Concerns
The need for additional financing presents the likelihood of further dilutive financing in the next few quarters.
Operational Strategy
The company is transitioning its go-to-market strategy to direct alliances with sleep medicine specialists, aiming to expand its sleep testing partnership nationally.
Vivos Therapeutics (VVOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.31M
Dividend YieldN/A
Average Volume (3M)100.17K
Price to Earnings (P/E)―
Beta (1Y)1.71
Revenue Growth9.47%
EPS Growth81.37%
CountryUS
Employees109
SectorHealthcare
Sector Strength42
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.45
Shares Outstanding5,889,520
10 Day Avg. Volume138,238
30 Day Avg. Volume100,171
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.22
Price to Sales (P/S)0.00
P/FCF Ratio-1.37
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue0.23
Enterprise Value/Gross Profit1.43
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$4.23Price Target Upside102.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Vivos Therapeutics Business Overview & Revenue Model
Company DescriptionVivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
How the Company Makes MoneyVivos Therapeutics generates revenue primarily through the sale of its proprietary oral appliance system, known as The Vivos System. This system is sold to dentists and healthcare providers who are trained and certified by Vivos to diagnose and treat patients with OSA using their products. The company charges fees for training and certification programs for dentists, which is an additional revenue stream. Vivos also benefits from ongoing sales of appliance components and consumables required during patient treatment. Strategic partnerships and collaborations with dental and medical practices further enhance their market reach and contribute to their revenue growth.
Vivos Therapeutics Financial Statement Overview
Summary
Vivos Therapeutics exhibits a mixed financial performance. The company shows positive revenue growth, but struggles with profitability and cash flow issues. The balance sheet has improved with increased equity, but high leverage remains a concern, indicating challenges in achieving financial stability and sustainable growth.Income Statement
Vivos Therapeutics has shown some positive revenue growth, with a 8.9% increase in 2024 compared to 2023. However, the company continues to face challenges in achieving profitability, indicated by negative EBIT and EBITDA margins, and a net income of zero in 2024. The consistent negative net profit margin over the years highlights ongoing operational struggles.45
Neutral
Balance Sheet
The balance sheet reflects improving equity, with stockholders' equity rising to $7.95 million in 2024 from $0.41 million in 2023, suggesting strengthened financial stability. However, the debt-to-equity ratio is relatively high, indicating potential leverage risks. The equity ratio remains moderate, demonstrating a balanced asset structure, but further stability is needed.55
Neutral
Cash Flow
The cash flow statement reveals persistent negative free cash flow, with minimal improvement over the years. Operating cash flow remains negative, highlighting ongoing cash burn, although financing activities have supported liquidity. The company needs to focus on improving operational efficiency to enhance cash flow stability.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 15.03M | 13.80M | 16.02M | 16.89M | 13.07M | Gross Profit |
| 9.02M | 8.27M | 10.02M | 12.60M | 10.41M | EBIT |
| -11.17M | -17.30M | -25.03M | -19.47M | -8.71M | EBITDA |
| -10.55M | -16.68M | -24.36M | -19.54M | -11.24M | Net Income Common Stockholders |
| -11.14M | -13.58M | -22.66M | -20.29M | -8.82M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 6.26M | 1.64M | 3.52M | 24.03M | 18.21M | Total Assets |
| 15.28M | 10.73M | 13.72M | 33.69M | 25.33M | Total Debt |
| 1.51M | 2.00M | 2.41M | 1.63M | 1.29M | Net Debt |
| -4.75M | 352.00K | -1.11M | -22.40M | -16.92M | Total Liabilities |
| 7.33M | 10.32M | 8.92M | 8.15M | 8.41M | Stockholders Equity |
| 7.95M | 411.00K | 4.80M | 25.54M | 16.92M |
| Cash Flow | Free Cash Flow | |||
| -13.26M | -12.75M | -20.51M | -18.13M | -5.80M | Operating Cash Flow |
| -12.69M | -11.95M | -19.59M | -15.73M | -5.68M | Investing Cash Flow |
| -568.00K | -853.00K | -924.00K | -2.61M | -120.25K | Financing Cash Flow |
| 17.88M | 10.92M | 0.00 | 24.17M | 23.54M |
Vivos Therapeutics Technical Analysis
Negative
2.09
Price Trends
2.74
Negative
3.41
Negative
3.25
Negative
Market Momentum
-0.13
Positive
40.51
Neutral
10.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 2.09 is below the 20-day moving average (MA) of 2.66, below the 50-day MA of 2.74, and below the 200-day MA of 3.25, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 40.51 is Neutral, neither overbought nor oversold. The STOCH value of 10.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.
Vivos Therapeutics Risk Analysis
Vivos Therapeutics disclosed 85 risk factors in its most recent earnings report. Vivos Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
The failure to expand our market penetration with DME distribution agreements would adversely affect our revenue and results of operations. Q4, 2023
2.
We face risks from negative publicity from unregistered oral appliances which has and may continue to hurt our sales. Q4, 2023
Vivos Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.03 | -43.89% | 2.83% | 16.75% | -0.06% | |
47 Neutral | $12.31M | ― | -450.47% | ― | 9.47% | 81.37% | |
43 Neutral | $11.24M | 0.92 | -499.57% | ― | -33.92% | ― | |
42 Neutral | $8.11M | ― | -56.80% | ― | -91.22% | 11.84% | |
41 Neutral | $17.69M | ― | -329.16% | ― | 2115.38% | -4.40% | |
34 Underperform | $116.00M | ― | 5400.35% | ― | 122.22% | 79.08% | |
24 Underperform | $259.67K | ― | ― | -2.99% | 59.87% |
* Healthcare Sector Average
Performance Comparison
VVOS
Vivos Therapeutics
2.28
0.18
8.57%
AXDXQ
Accelerate Diagnostics
0.01
-1.37
-99.28%
CODX
Co-Diagnostics
0.23
-0.83
-78.30%
PAVM
PAVmed
0.65
-1.08
-62.43%
BSGM
BioSig Technologies
5.28
3.55
205.20%
ADGM
Adagio Medical Holdings
1.19
-10.25
-89.60%
Vivos Therapeutics Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q1-2025)
| % Change Since: -31.70%|
Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment Neutral
The call outlined significant strategic shifts and growth potential through the SCN acquisition and pediatric product line, but financial challenges remain with declining service revenue, increased losses, and reduced cash reserves. The Rebis alliance's underperformance also highlights potential integration risks.Q1-2025 Updates
Positive Updates
Pediatric Guide Appliance Line Growth
Total arches shipped grew 87% from 1,996 in the same period last year to 3,736 this year. Product revenue for the quarter was up 8% due to lower price points on certain pediatric products.
SCN Acquisition Potential
Acquisition of the Sleep Center of Nevada is expected to close in the next month or two, potentially adding diagnostics and treatment revenue. SCN sees approximately 3,000 sleep patients a month.
Strategic Shift to Sleep Medical Providers
Transitioning to a model of creating strategic alliances or acquiring sleep medical providers to drive sales and diversify revenue.
Cost Reduction Initiatives
Sales and marketing expenses decreased from $700,000 to $400,000, and total operating expenses decreased by 5% compared to last year due to cost-cutting initiatives.
Negative Updates
Decline in Service Revenue
Total revenue decreased from $3.4 million in the first quarter of 2024 to $3 million in 2025, driven by a decline in service and VIP enrollment revenue.
Operating and Net Loss
Operating loss increased slightly to $3.9 million from $3.8 million in the prior year. Net loss for the first quarter of 2025 was $3.9 million compared to $3.8 million for the first quarter of 2024.
Cash Position Decrease
Cash and cash equivalents decreased significantly from $6.3 million as of December 31, 2024, to $2.3 million as of March 31, 2025.
Rebis Alliance Underperformance
The strategic alliance with Rebis Health has progressed more slowly than expected due to internal issues, affecting patient volume and revenue.
Company Guidance
During the first quarter of 2025 earnings call, Vivos Therapeutics provided guidance on several key metrics and strategic developments. CEO Kirk Huntsman highlighted a significant pivot in their business model, focusing on creating alliances with or acquiring sleep medical providers to drive sales of their OSA treatment appliances and diversify revenue. Product sales, particularly in the pediatric guide appliance line, saw an 87% increase in arches shipped compared to the previous year, despite an 8% rise in product revenue due to lower price points. The company anticipates closing the acquisition of the Sleep Center of Nevada, which tests approximately 3,000 patients monthly for sleep disorders, within the next month or two. This acquisition is expected to be accretive to revenue and gross profit, with an anticipated net contribution margin of 50% or better. Vivos has signed a non-binding term sheet for a $7.5 million senior loan to support this acquisition and is actively seeking a $1.5 million equity infusion. The company also reported a $3.9 million net loss for the first quarter of 2025, with total revenue decreasing to $3 million from $3.4 million in the prior year, reflecting their strategic pivot and cost-cutting initiatives.Vivos Therapeutics Corporate Events
Executive/Board ChangesPrivate Placements and FinancingBusiness Operations and Strategy
Vivos Therapeutics Enters Market Offering Agreement with Wainwright
Neutral
Feb 14, 2025
On February 14, 2025, Vivos Therapeutics, Inc. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., allowing the company to sell shares of its common stock valued up to $3,328,881 through the Nasdaq Capital Market. This move is part of the company’s strategy to raise capital, with Wainwright acting as the sales agent under specific conditions and commission agreements. Additionally, the company amended employment agreements for its CEO and CFO, effective January 1, 2025, as part of an ongoing effort to align executive compensation with company goals.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.